Core Viewpoint - The event hosted by Kexi Pharmaceutical highlighted the company's advancements in CAR-T cell therapy, its core industry layout, and future development plans, showcasing its competitive strengths and industry prospects [1]. Group 1: CAR-T Technology Development - Kexi Pharmaceutical focuses on addressing key challenges in CAR-T therapy, including immune rejection, low patient accessibility, and balancing efficacy with safety [4]. - The company aims to prioritize clinical needs by targeting difficult-to-treat cancers such as pancreatic cancer and leukemia, while also optimizing technology to reduce treatment costs and improve patient access [4]. - Kexi is developing multi-target universal CAR-T candidates that cover solid tumors, hematological cancers, and autoimmune diseases, involving multiple key targets [4]. Group 2: Production and Operational Strategy - The company plans to establish an integrated intelligent cell manufacturing center capable of producing both autologous and allogeneic CAR-T cells, with an expected annual capacity to serve tens of thousands of patients [4]. - Kexi aims to focus on process automation, management information systems, and supply chain collaboration to continuously lower production costs and enhance product quality [5]. Group 3: Business Development and Strategic Partnerships - Kexi Pharmaceutical has seen a surge in business development (BD) transactions, which have become a significant revenue source for biopharmaceutical companies [5]. - The company emphasizes that the success of BD partnerships relies on product competitiveness and corporate strength rather than external factors, maintaining strong relationships with multinational companies [5]. - Kexi has strategically invested in Ukaize Biomedical (Shanghai) Co., Ltd., enhancing its ecosystem in cell therapy and laying a solid foundation for future technological collaboration and industry expansion [5].
科济药业：全力推进通用型CAR-T产品开发 降低患者诊疗成本